Vaxil Bio Ltd. Blog | Talkmarkets | Page 1
No data available
No data available

People who follow this stock (17)

Latest Posts

About This Stock More About This Stock
Vaxil Bio's ImMucin Is A Novel Neoantigen With Significant Anticancer Potential
Article By: Jason Napodano
Monday, December 12, 2016 11:33 AM EST
ImMucin is expected to qualify as an Orphan Drug in the U.S., which will provide certain cost and time advantages to development, as well as market exclusivity one approved. I expect the company to move into Phase 2 in 2017.
In this article: VXLLF
Read

Latest Tweets for $VXLLF

No tweets yet!